WO2013033206A3 - Compositions and methods for inhibiting ccl3 - Google Patents

Compositions and methods for inhibiting ccl3 Download PDF

Info

Publication number
WO2013033206A3
WO2013033206A3 PCT/US2012/052854 US2012052854W WO2013033206A3 WO 2013033206 A3 WO2013033206 A3 WO 2013033206A3 US 2012052854 W US2012052854 W US 2012052854W WO 2013033206 A3 WO2013033206 A3 WO 2013033206A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccl3
myeloid
pathologies associated
compositions
methods
Prior art date
Application number
PCT/US2012/052854
Other languages
French (fr)
Other versions
WO2013033206A2 (en
Inventor
Benjamin J. FRISCH
Laura M. Calvi
Michael W. BECKER
Original Assignee
University Of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Rochester filed Critical University Of Rochester
Publication of WO2013033206A2 publication Critical patent/WO2013033206A2/en
Priority to US14/194,344 priority Critical patent/US20140186376A1/en
Publication of WO2013033206A3 publication Critical patent/WO2013033206A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the discovery that CCL3, through at least one of its receptors CCRl and CCR5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia. Interfering with the interaction between CCL3 and its receptors, by targeting at least one of CCL3, CCRl, CCR5, diminishes the effects of pathologies associated with myeloid neoplasms. In various embodiments, the myeloid neoplasm is a myeloproliferative disorder, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), or myelodysplasia syndrome (MDS).
PCT/US2012/052854 2011-08-29 2012-08-29 Compositions and methods for inhibiting ccl3 WO2013033206A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/194,344 US20140186376A1 (en) 2012-08-29 2014-02-28 Compositions and Methods for Inhibiting CCL3

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528410P 2011-08-29 2011-08-29
US61/528,410 2011-08-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/194,344 Continuation-In-Part US20140186376A1 (en) 2012-08-29 2014-02-28 Compositions and Methods for Inhibiting CCL3

Publications (2)

Publication Number Publication Date
WO2013033206A2 WO2013033206A2 (en) 2013-03-07
WO2013033206A3 true WO2013033206A3 (en) 2014-05-08

Family

ID=47757154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/052854 WO2013033206A2 (en) 2011-08-29 2012-08-29 Compositions and methods for inhibiting ccl3

Country Status (1)

Country Link
WO (1) WO2013033206A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700334A4 (en) * 2017-10-27 2021-07-21 Transfusion Health, LLC Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246208A1 (en) * 2006-01-05 2009-10-01 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20100305043A1 (en) * 2007-04-26 2010-12-02 Univeristy Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
US20100317592A1 (en) * 2001-12-18 2010-12-16 Jean-Philippe Girard Chemokine-binding protein and methods of use
US20110059107A1 (en) * 2009-08-28 2011-03-10 Vlst Corporation Antikine antibodies that bind to multiple cc chemokines
US20110070219A1 (en) * 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
US20110098212A1 (en) * 2005-05-25 2011-04-28 Ursula Gompels Cytokine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100317592A1 (en) * 2001-12-18 2010-12-16 Jean-Philippe Girard Chemokine-binding protein and methods of use
US20110098212A1 (en) * 2005-05-25 2011-04-28 Ursula Gompels Cytokine
US20090246208A1 (en) * 2006-01-05 2009-10-01 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20100305043A1 (en) * 2007-04-26 2010-12-02 Univeristy Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
US20110070219A1 (en) * 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
US20110059107A1 (en) * 2009-08-28 2011-03-10 Vlst Corporation Antikine antibodies that bind to multiple cc chemokines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOI ET AL.: "Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease.", J CLIN INVEST., vol. 108, no. 12, 2001, pages 1833 - 41 *
DATABASE UNIPROT April 2011 (2011-04-01), "CCL3_HUMAN.", retrieved from http://www.uniprot.org/uniprot/P10147.txt?version=130 accession no. 10147. *
FRISCH ET AL.: "Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.", BLOOD, vol. 119, no. 2, 28 September 2011 (2011-09-28), pages 540 - 550 *
RAJE ET AL.: "Advances in the biology and treatment of bone disease in multiple myeloma.", CLIN CANCER RES., vol. 17, no. 6, March 2011 (2011-03-01), pages 1278 - 1286, XP055006243, DOI: doi:10.1158/1078-0432.CCR-10-1804 *

Also Published As

Publication number Publication date
WO2013033206A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
IN2014DN10049A (en)
HK1154568A1 (en) A process for the preparation of the apoptosis promoter abt-263
ECSP14013327A (en) COMPOUNDS WITH NEMATICIATED ACTIVITY
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
IN2014CN04160A (en)
TR201818613T4 (en) Process for the purification of (hydro) fluoroalkenes.
EA201590887A1 (en) COMPOSITION
JO3154B1 (en) Trpv4 antagonists
MX2015007518A (en) Methods for treating pruritus.
MX2019011805A (en) Melon plants with melon yellowing associated virus (myav) resistance.
MX337721B (en) Heteroaryl compounds as 5-ht4 receptor ligands.
WO2013065018A3 (en) Gas burner, in particular for a cooking appliance
MX360872B (en) Novel compositions for producing cast polyamides.
WO2012008783A3 (en) Air knife chamber having shield member
WO2013033206A3 (en) Compositions and methods for inhibiting ccl3
MY151180A (en) Electrocoating composition comprising a crater control additive
IN2012DN03898A (en)
GEP201706708B (en) Isoxazolidine derivatives
IN2012DE00599A (en)
MX348867B (en) Chemical compounds.
MX337487B (en) Woody odorants.
WO2014041437A3 (en) Production of biokerosene with hyperthermophilic organisms
IN2013MU03755A (en)
MX351789B (en) New composition for producing cast polyamides.
MY174887A (en) (6r,10r)-6,10,14-trimetylpentadecan-2-one prepared from (r)-3,7-dimetyloct-6-enal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12827306

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12827306

Country of ref document: EP

Kind code of ref document: A2